DK1572167T3 - Transdermal buprenophindoseringsbehandlingsplan for analgesi - Google Patents

Transdermal buprenophindoseringsbehandlingsplan for analgesi

Info

Publication number
DK1572167T3
DK1572167T3 DK03813444T DK03813444T DK1572167T3 DK 1572167 T3 DK1572167 T3 DK 1572167T3 DK 03813444 T DK03813444 T DK 03813444T DK 03813444 T DK03813444 T DK 03813444T DK 1572167 T3 DK1572167 T3 DK 1572167T3
Authority
DK
Denmark
Prior art keywords
buprenorphine
dosage form
dosage
transdermal
buprenophine
Prior art date
Application number
DK03813444T
Other languages
Danish (da)
English (en)
Inventor
Bruce E Reidenberg
Daniel A Spyker
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK1572167T3 publication Critical patent/DK1572167T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03813444T 2002-12-13 2003-12-15 Transdermal buprenophindoseringsbehandlingsplan for analgesi DK1572167T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43342302P 2002-12-13 2002-12-13
PCT/US2003/039792 WO2004054553A1 (en) 2002-12-13 2003-12-15 Transdermal buprenorphine dosage regimen for analgesia

Publications (1)

Publication Number Publication Date
DK1572167T3 true DK1572167T3 (da) 2008-10-13

Family

ID=32595187

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03813444T DK1572167T3 (da) 2002-12-13 2003-12-15 Transdermal buprenophindoseringsbehandlingsplan for analgesi

Country Status (16)

Country Link
US (1) US7270830B2 (cg-RX-API-DMAC7.html)
EP (1) EP1572167B1 (cg-RX-API-DMAC7.html)
JP (2) JP5054893B2 (cg-RX-API-DMAC7.html)
AT (1) ATE400258T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003297073A1 (cg-RX-API-DMAC7.html)
CA (1) CA2510223C (cg-RX-API-DMAC7.html)
CY (1) CY1108384T1 (cg-RX-API-DMAC7.html)
DE (1) DE60322102D1 (cg-RX-API-DMAC7.html)
DK (1) DK1572167T3 (cg-RX-API-DMAC7.html)
ES (1) ES2310262T3 (cg-RX-API-DMAC7.html)
IL (1) IL169056A (cg-RX-API-DMAC7.html)
MX (1) MXPA05006334A (cg-RX-API-DMAC7.html)
NZ (1) NZ539936A (cg-RX-API-DMAC7.html)
PT (1) PT1572167E (cg-RX-API-DMAC7.html)
SI (1) SI1572167T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004054553A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
US7270830B2 (en) * 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
BRPI0409945A (pt) * 2003-04-30 2006-04-25 Purdue Pharma Lp forma de dosagem resistente à alteração
CA2529983C (en) * 2003-07-25 2010-07-20 Euro-Celtique S.A. Preoperative treatment of post operative pain
DE602004009449T2 (de) 2003-07-25 2008-07-24 Euro-Celtique S.A. Behandlung von entzug
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US9522188B2 (en) * 2005-12-13 2016-12-20 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
ES2577390T3 (es) 2006-07-21 2016-07-14 Biodelivery Sciences International, Inc. Dispositivos de administración transmucosa con mayor captación
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
EP2262367A4 (en) * 2008-03-08 2011-04-20 Theraquest Biosciences Inc PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
WO2010047681A1 (en) * 2008-10-24 2010-04-29 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
MX352959B (es) 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
EA201491164A1 (ru) * 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
MX2018010367A (es) * 2016-02-29 2018-12-10 Guenenthal Gmbh Titulacion de cebranopadol.
WO2020124073A1 (en) * 2018-12-14 2020-06-18 Pear Therapeutics, Inc. A digital therapeutic component to optimize induction of buprenorphine-containing products

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA856002B (en) * 1984-08-10 1987-04-29 Du Pont Transdermal delivery of opioids
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
AU637496B2 (en) 1990-04-24 1993-05-27 Teijin Limited Plaster
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
JP2886021B2 (ja) * 1993-03-19 1999-04-26 帝三製薬株式会社 安定な貼付剤
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
JP2837337B2 (ja) * 1993-08-10 1998-12-16 帝三製薬株式会社 貼付剤
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
JP3662388B2 (ja) * 1997-05-30 2005-06-22 日東電工株式会社 経皮吸収製剤及びその製造方法
PT1485051E (pt) 2002-03-20 2008-07-09 Euro Celtique Sa Processo de administração da buprenorfina para o tratamento da depressão
US7270830B2 (en) * 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
DE602004009449T2 (de) 2003-07-25 2008-07-24 Euro-Celtique S.A. Behandlung von entzug

Also Published As

Publication number Publication date
JP2006513184A (ja) 2006-04-20
PT1572167E (pt) 2008-10-03
CA2510223C (en) 2017-09-12
ATE400258T1 (de) 2008-07-15
JP5054893B2 (ja) 2012-10-24
AU2010201479A1 (en) 2010-05-06
ES2310262T3 (es) 2009-01-01
SI1572167T1 (sl) 2008-12-31
US20040126416A1 (en) 2004-07-01
AU2003297073A1 (en) 2004-07-09
JP2010285457A (ja) 2010-12-24
WO2004054553A9 (en) 2005-09-15
WO2004054553A1 (en) 2004-07-01
EP1572167A1 (en) 2005-09-14
DE60322102D1 (de) 2008-08-21
EP1572167B1 (en) 2008-07-09
EP1572167A4 (en) 2007-01-10
CY1108384T1 (el) 2014-02-12
NZ539936A (en) 2007-06-29
IL169056A (en) 2012-01-31
MXPA05006334A (es) 2005-08-26
CA2510223A1 (en) 2004-07-01
AU2010201479B2 (en) 2012-11-01
US7270830B2 (en) 2007-09-18

Similar Documents

Publication Publication Date Title
SI1572167T1 (sl) Transdermalni buprenorfinski dozirni reĹľim za analgezijo
IS6702A (is) Fentanyl lyfjablanda til lyfjagjafar í nef
DK1032376T3 (da) Anvendelse af benzhydrylsulfinylderivater til behandling af søvnighed af medicinal oprindelse
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
NO20006604L (no) Fremgangsmåter og transdermale sammensetninger for lindring av smerte
DK1646328T3 (da) Behandling af afhængighedsophör
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
DK1485051T3 (da) Fremgangsmåde til indgivelse af buprenorphin til behandling af depression
NO962655L (no) Deutrerte virkestoffer i transdermal applikasjon
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
RU2002103808A (ru) Способ лечения болевого синдрома у онкологических больных
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
SE0203817D0 (sv) New composition
RU94032792A (ru) Применение 5нтiа - антагонистов для прекращения использования табака
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
ATE371446T1 (de) Zusammensetzungen zur verhinderung der adhäsion
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
MX9804798A (es) Nuevos compuestos con efecto analgesico.
MX9804797A (es) Nuevos compuestos con efecto analgesico.
TH60393A (th) การบัดบัดรักษาอาการเจ็บปวด
RU98111518A (ru) Способ лечения хронического полимиозита